Indianapolis, IN – Pharmaceutical giant Eli Lilly has announced a definitive agreement to acquire AtaiBeckley, a clinical-stage biotechnology company focused…
Read More
Novo Nordisk Sues Eli Lilly Over Alleged Deceptive Advertising of Obesity Drugs
The escalating rivalry between pharmaceutical giants Novo Nordisk and Eli Lilly has reached a new legal frontier, with Novo Nordisk…
Read More
BMS claims pharma’s most powerful AI supercomputer. How it stacks up to Lilly’s and Roche’s.
Bristol Myers Squibb (BMS) announced Monday its plans to deploy an NVIDIA DGX SuperPOD, a cutting-edge, prepackaged supercomputing platform designed…
Read More
Eli Lilly Acquires AtaiBeckley for $2.8 Billion, Marking Entry into Psychedelic Therapeutics
In a landmark move that signals a significant shift in pharmaceutical investment, Eli Lilly and Company has announced the acquisition…
Read More
Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo
Eli Lilly and Company has announced groundbreaking Phase 3 results for its investigational triple agonist, retatrutide, demonstrating significant efficacy in…
Read More
Lilly offers up to $3.8 billion for AtaiBeckley in bet on ‘God molecule’ found in toad venom
Eli Lilly has formally agreed to acquire AtaiBeckley for a substantial sum, comprising $2.8 billion upfront and an additional $1…
Read More
Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo
Eli Lilly has significantly bolstered its position in the competitive metabolic disease landscape with detailed Phase 3 results for its…
Read More
Lilly’s retatrutide shows 28.3% weight loss, but increased side effects
Eli Lilly’s experimental triple hormone receptor agonist, retatrutide, has recently captured significant attention within the medical and pharmaceutical communities following…
Read More
Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo
Eli Lilly and Company utilized the prestigious platform of the American Diabetes Association’s (ADA) annual meeting to unveil groundbreaking Phase…
Read More
Eli Lilly’s Retatrutide Demonstrates Superior Weight Loss Efficacy Amidst Elevated Side Effect Profile in Phase 3 Trials
INDIANAPOLIS, IN – Eli Lilly and Company has announced groundbreaking Phase 3 trial results for its investigational drug, retatrutide, a…
Read MoreYOU MAY HAVE MISSED
